

Cancer Immunotherapy: Technologies and Global Markets

<https://marketpublishers.com/r/C0186169B4D2EN.html>

Date: April 2025

Pages: 203

Price: US\$ 4,650.00 (Single User License)

ID: C0186169B4D2EN

Abstracts

Report Scope

This report provides a detailed analysis of the cancer immunotherapy market. It highlights cancer immunotherapy's current and future market potential and analyzes the competitive environment, covering regulatory scenarios, drivers, restraints and opportunities. The report provides market trends in cancer immunotherapy for the forecast period 2024–2029 using data from 2023 and estimates from 2024. It includes projections of compound annual growth rates (CAGRs) through 2029 and provides the market shares of key players in this market.

In this analysis, the cancer immunotherapy market is segmented by therapy types, cancer types and geographic regions. By therapy type, the market is segmented into the following: checkpoint inhibitors, monoclonal antibodies, adoptive cell therapies, cytokine therapy, cancer vaccines, oncolytic virus therapy and other immunotherapies. It is segmented by cancer type into melanoma, leukemia, lymphoma, myeloma, lung cancer, breast cancer, colorectal cancer and other cancers.

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The regional analysis includes details about major countries such as the U.S., Canada, Germany, the U.K., Italy, Spain, France, Japan, China, South Korea, Australia and India.

The report aims to:

Analyze therapies and types of cancer.

Analyze global market size and segmentation.

Understand market constraints and drivers.

Provide detailed market forecasts for 2029.

Assess market shares, competitiveness and industry structure.

Identify potential long-term impacts on the cancer immunotherapy market.

Report Includes

75 data tables and 54 additional tables

An analysis of the global cancer immunotherapy market

Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029

Estimates of the market size and revenue prospects for the global market, along with a market share analysis by therapy type, cancer type, and region

Coverage of treatments that are in development for late-stage and early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends

Evaluation of recent patent activity and key granted and published patents in the industry

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies

Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

Profiles of leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., and AstraZeneca

Contents

CHAPTER 1 EXECUTIVE SUMMARY

Market Outlook
Scope of Report
Market Summary

CHAPTER 2 MARKET OVERVIEW

Overview
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry
Key Concepts of Immunotherapy

CHAPTER 3 MARKET DYNAMICS

Market Dynamics
Market Drivers
Rising Cancer Cases Globally
Robust Approval of Immunotherapy Drugs
Rise in Government Funding and Pharmaceutical R&D Spending
Market Restraints
High Cost of Immunotherapy
Loss of Exclusivity and Genericismation
Shortage of Oncology Professionals
Market Opportunities
Technological Advances in Immunotherapy
Potential in Cancer Immunotherapy

CHAPTER 4 REGULATORY LANDSCAPE

Overview
U.S.
Europe

Japan

CHAPTER 5 EMERGING TECHNOLOGIES

Overview

Artificial Intelligence (AI)

Emergent Biomarkers

Immunotherapy Pipeline

Patent Analysis

Future Prospects

CHAPTER 6 MARKET SEGMENTATION ANALYSIS

Segmentation Breakdown

Global Market for Cancer Immunotherapy, by Therapy Type

Global Market Size and Forecast

Checkpoint Inhibitors

Monoclonal Antibodies

Adoptive Cell Therapies

Cytokine Therapy

Cancer Vaccines

Oncolytic Virus Therapy

Other Immunotherapies

Global Market for Cancer Immunology, by Cancer Type

Global Market Size and Forecast

Melanoma

Leukemia

Lymphoma

Myeloma

Lung Cancer

Breast Cancer

Colorectal Cancer

Other Cancers

Geographic Breakdown

Global Market for Cancer Immunotherapy, by Region

Global Market Size and Forecast

North America

Europe

Asia-Pacific

Rest of the World

CHAPTER 7 COMPETITIVE INTELLIGENCE

Overview

Competitive Landscape

Company Share Analysis

CHAPTER 8 SUSTAINABILITY IN CANCER IMMUNOTHERAPY MARKET: AN ESG PERSPECTIVE

Introduction to ESG

Role of ESG in the Pharma Industry

Sustainability in the Cancer Immunotherapy Market

ESG Perspective

Environmental Impact

Social Impact

Governance Impact

ESG Risk Ratings

Conclusion

CHAPTER 9 APPENDIX

Methodology

Abbreviations

Sources

Company Profiles

ABBVIE INC.

AMGEN INC.

ASTRAZENECA

BRISTOL-MYERS SQUIBB CO.

F. HOFFMANN-LA ROCHE LTD.

GILEAD SCIENCES INC.

JOHNSON & JOHNSON SERVICES INC.

LILLY

MERCK & CO. INC.

NOVARTIS AG

PFIZER INC.

REGENERON PHARMACEUTICALS INC.

SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.

List Of Tables

LIST OF TABLES

Summary Table : Global Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 1 : Porter's Five Forces Analysis: Cancer Immunotherapy Market

Table 2 : Average Price of Immunotherapy

Table 3 : List of Selected Clinical Trial Studies on Immunotherapy, 2025

Table 4 : List of Selected Recent Patents Related to Immunotherapy 2024-2025

Table 5 : Global Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 6 : FDA-Approved Immune Checkpoint Inhibitors 2015–2018

Table 7 : Global Market for Checkpoint Inhibitors in Cancer Immunotherapy, by Region, Through 2029

Table 8 : Global Market for Checkpoint Inhibitors in Cancer Immunotherapy, by Type, Through 2029

Table 9 : Global Market for Monoclonal Antibodies in Cancer Immunotherapy, by Region, Through 2029

Table 10 : Global Market for Adoptive Cell Therapies in Cancer Immunotherapy, by Region, Through 2029

Table 11 : Global Market for Cytokine Therapy in Cancer Immunotherapy, by Region, Through 2029

Table 12 : Global Market for Cancer Vaccines in Cancer Immunotherapy, by Region, Through 2029

Table 13 : Players Investing in Oncolytic Virology, 2024

Table 14 : Global Market for Oncolytic Virus Therapy in Cancer Immunotherapy, by Region, Through 2029

Table 15 : Global Market for Other Immunotherapies in Cancer Immunotherapy, by Region, Through 2029

Table 16 : Global Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 17 : Global Market for Cancer Immunotherapy in Melanoma, by Region, Through 2029

Table 18 : Global Market for Cancer Immunotherapy in Leukemia, by Region, Through 2029

Table 19 : Global Market for Cancer Immunotherapy in Lymphoma, by Region, Through 2029

Table 20 : Global Market for Cancer Immunotherapy in Myeloma, by Region, Through 2029

Table 21 : Global Market for Cancer Immunotherapy in Lung Cancer, by Region,

Through 2029

Table 22 : Global Market for Cancer Immunotherapy in Breast Cancer, by Region, Through 2029

Table 23 : Global Market for Cancer Immunotherapy in Colorectal Cancer, by Region, Through 2029

Table 24 : Global Market for Cancer Immunotherapy in Other Cancers, by Region, Through 2029

Table 25 : Global Market for Cancer Immunotherapy, by Region, Through 2029

Table 26 : North American Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 27 : North American Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 28 : North American Market for Cancer Immunotherapy, by Country, Through 2029

Table 29 : U.S. Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 30 : U.S. Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 31 : Canadian Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 32 : Canadian Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 33 : Mexican Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 34 : Mexican Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 35 : European Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 36 : European Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 37 : European Market for Cancer Immunotherapy, by Country, Through 2029

Table 38 : German Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 39 : German Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 40 : U.K. Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 41 : U.K. Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 42 : French Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 43 : French Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 44 : Italian Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 45 : Italian Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 46 : Spanish Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 47 : Spanish Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 48 : Rest of European Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 49 : Rest of European Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 50 : Asia-Pacific Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 51 : Asia-Pacific Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 52 : Asia-Pacific Market for Cancer Immunotherapy, by Country, Through 2029

Table 53 : Chinese Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 54 : Chinese Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 55 : Japanese Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 56 : Japanese Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 57 : Indian Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 58 : Indian Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 59 : Australian Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 60 : Australian Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 61 : Rest of Asia-Pacific Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 62 : Rest of Asia-Pacific Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 63 : Rest of the World Market for Cancer Immunotherapy, by Therapy Type, Through 2029

Table 64 : Rest of the World Market for Cancer Immunotherapy, by Cancer Type, Through 2029

Table 65 : Key Focus Areas in ESG Metrics

Table 66 : ESG Rankings for Leading Companies in Cancer Immunotherapy Market, 2024*

Table 67 : Abbreviations Used in this Report.

Table 68 : Report Sources

Table 69 : AbbVie Inc.: Company Snapshot

Table 70 : AbbVie Inc.: Financial Performance, FY 2022 and 2023

Table 71 : AbbVie Inc.: Product Portfolio

Table 72 : AbbVie Inc.: News/Key Developments, 2023 and 2024

Table 73 : Amgen Inc.: Company Snapshot

Table 74 : Amgen Inc.: Financial Performance, FY 2022 and 2023

Table 75 : Amgen Inc.: Product Portfolio

Table 76 : Amgen Inc.: News/Key Developments, 2022-2024

Table 77 : AstraZeneca: Company Snapshot

Table 78 : AstraZeneca: Financial Performance, FY 2022 and 2023

- Table 79 : AstraZeneca: Product Portfolio
- Table 80 : AstraZeneca: News/Recent Developments, 2023 and 2024
- Table 81 : Bristol-Myers Squibb Co.: Company Snapshot
- Table 82 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
- Table 83 : Bristol-Myers Squibb Co.: Product Portfolio
- Table 84 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024
- Table 85 : F. Hoffmann-La Roche Ltd.: Company Snapshot
- Table 86 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
- Table 87 : F. Hoffmann-La Roche Ltd.: Product Portfolio
- Table 88 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022–2024
- Table 89 : Gilead Sciences Inc.: Company Snapshot
- Table 90 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
- Table 91 : Gilead Sciences Inc.: Product Portfolio
- Table 92 : Gilead Sciences Inc.: News/Key Developments, 2023 and 2024
- Table 93 : Johnson & Johnson Services Inc.: Company Snapshot
- Table 94 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
- Table 95 : Johnson & Johnson Services Inc.: Product Portfolio
- Table 96 : Johnson & Johnson Services Inc.: News/Key Developments, 2022?2024
- Table 97 : Lilly: Company Snapshot
- Table 98 : Lilly: Financial Performance, FY 2022 and 2023
- Table 99 : Lilly: Product Portfolio
- Table 100 : Lilly: News/Key Developments, 2022 and 2023
- Table 101 : Merck & Co. Inc.: Company Snapshot
- Table 102 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
- Table 103 : Merck & Co. Inc.: Product Portfolio
- Table 104 : Merck & Co. Inc.: News/Key Developments, 2021–2024
- Table 105 : Novartis AG: Company Snapshot
- Table 106 : Novartis AG: Financial Performance, FY 2022 and 2023
- Table 107 : Novartis AG: Product Portfolio
- Table 108 : Novartis AG: News/Key Developments, 2022
- Table 109 : Pfizer Inc.: Company Snapshot
- Table 110 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
- Table 111 : Pfizer Inc.: Product Portfolio
- Table 112 : Pfizer Inc.: News/Key Developments, 2023 and 2024
- Table 113 : Regeneron Pharmaceuticals Inc.: Company Snapshot
- Table 114 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
- Table 115 : Regeneron Pharmaceuticals Inc.: Product Portfolio
- Table 116 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2024

Table 117 : Sanofi: Company Snapshot

Table 118 : Sanofi: Financial Performance, FY 2022 and 2023

Table 119 : Sanofi: Product Portfolio

Table 120 : Sanofi: News/Key Developments, 2022–2024

Table 121 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot

Table 122 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023

Table 123 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio

Table 124 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023

Table 125 : Teva Pharmaceutical Industries Ltd.: Company Snapshot

Table 126 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023

Table 127 : Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 128 : Few Emerging Players in Cancer Immunotherapy Market

List Of Figures

LIST OF FIGURES

Summary Figure : Global Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 1 : Snapshot of Market Dynamics

Figure 2 : Distribution Share of the Most Frequent Cancer Types in Women*, 2022

Figure 3 : Distribution Share of the Most Frequent Cancer Types in Men*, 2022

Figure 4 : Estimated New Cancer Cases and Deaths in the U.S. in 2024

Figure 5 : National Cancer Institute Research Funding, 2012-2019

Figure 6 : Global Pharmaceutical R&D Spending and Growth, 2020-2026

Figure 7 : Immunotherapy-Related Patents and Publications in the U.S. and China

Figure 8 : Global Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 9 : Global Market Shares of Checkpoint Inhibitors in Cancer Immunotherapy, by Region, 2023

Figure 10 : Global Market Shares of Checkpoint Inhibitors in Cancer Immunotherapy, by Type, 2023

Figure 11 : Global Market Shares of Monoclonal Antibodies in Cancer Immunotherapy, by Region, 2023

Figure 12 : Global Market Shares of Adoptive Cell Therapies in Cancer Immunotherapy, by Region, 2023

Figure 13 : Global Market Shares of Cytokine Therapy in Cancer Immunotherapy, by Region, 2023

Figure 14 : Global Market Shares of Cancer Vaccines in Cancer Immunotherapy, by Region, 2023

Figure 15 : Global Market Shares of Oncolytic Virus Therapy in Cancer Immunotherapy, by Region, 2023

Figure 16 : Global Market Shares of Other Immunotherapies in Cancer Immunotherapy, by Region, 2023

Figure 17 : Global Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 18 : Global Market Shares of Cancer Immunotherapy in Melanoma, by Region, 2023

Figure 19 : Global Market Shares of Cancer Immunotherapy in Leukemia, by Region, 2023

Figure 20 : Global Market Shares of Cancer Immunotherapy in Lymphoma, by Region, 2023

Figure 21 : Global Market Shares of Cancer Immunotherapy in Myeloma, by Region, 2023

Figure 22 : Global Market Shares of Cancer Immunotherapy in Lung Cancer, by Region, 2023

Figure 23 : Global Market Shares of Cancer Immunotherapy in Breast Cancer, by Region, 2023

Figure 24 : Global Market Shares of Cancer Immunotherapy in Colorectal Cancer, by Region, 2023

Figure 25 : Global Market Shares of Cancer Immunotherapy in Other Cancers, by Region, 2023

Figure 26 : Global Market Shares of Cancer Immunotherapy, by Region, 2023

Figure 27 : North American Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 28 : North American Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 29 : North American Market Shares of Cancer Immunotherapy, by Country, 2023

Figure 30 : U.S. Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 31 : U.S. Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 32 : Canadian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 33 : Canadian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 34 : Mexican Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 35 : Mexican Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 36 : European Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 37 : European Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 38 : European Market Shares of Cancer Immunotherapy, by Country, 2023

Figure 39 : German Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 40 : German Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 41 : U.K. Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 42 : U.K. Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 43 : French Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 44 : French Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 45 : Italian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 46 : Italian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 47 : Spanish Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 48 : Spanish Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 49 : Rest of European Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 50 : Rest of European Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 51 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 52 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 53 : Asia-Pacific Market Shares of Cancer Immunotherapy, by Country, 2023

Figure 54 : Chinese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 55 : Chinese Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 56 : Japanese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 57 : Japanese Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 58 : Indian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 59 : Indian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 60 : Australian Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 61 : Australian Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 62 : Rest of Asia-Pacific Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 63 : Rest of Asia-Pacific Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 64 : Rest of the World Market Shares of Cancer Immunotherapy, by Therapy Type, 2023

Figure 65 : Rest of the World Market Shares of Cancer Immunotherapy, by Cancer Type, 2023

Figure 66 : Top 10 Blockbuster Cancer Immunotherapy Products, by Sales Revenue, 2022-2023

Figure 67 : Global Market Shares of Cancer Immunotherapy, by Company, 2023

Figure 68 : Pillars of ESG

Figure 69 : Advantages of ESG for Companies

Figure 70 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023

Figure 71 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023

Figure 72 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023

Figure 73 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023

Figure 74 : AstraZeneca: Revenue Share, by Business Unit, FY 2023

Figure 75 : AstraZeneca: Revenue Share, by Region/Country, FY 2023

Figure 76 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023

Figure 77 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023

Figure 78 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023

Figure 79 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023

Figure 80 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023

Figure 81 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023

Figure 82 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023

Figure 83 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023

2023

Figure 84 : Lilly: Revenue Share, by Business Unit, FY 2023

Figure 85 : Lilly: Revenue Share, by Country/Region, FY 2023

Figure 86 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023

Figure 87 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023

Figure 88 : Novartis AG: Revenue Share, by Business Unit, FY 2023

Figure 89 : Novartis AG: Revenue Share, by Country/Region, FY 2023

Figure 90 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023

Figure 91 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023

Figure 92 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023

Figure 93 : Regeneron Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023

Figure 94 : Sanofi: Revenue Share, by Business Unit, FY 2023

Figure 95 : Sanofi: Revenue Share, by Country/Region, FY 2023

Figure 96 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Business Unit, FY 2023

Figure 97 : Takeda Pharmaceutical Co. Ltd.: Revenue Share, by Region, FY 2023

Figure 98 : Teva Pharmaceutical Industries Ltd.: Market Share, by Business Unit, FY 2023

Figure 99 : Teva Pharmaceutical Industries Ltd.: Market Share, by Country/Region, FY 2023

I would like to order

Product name: Cancer Immunotherapy: Technologies and Global Markets

Product link: <https://marketpublishers.com/r/C0186169B4D2EN.html>

Price: US\$ 4,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C0186169B4D2EN.html>